Educational analysis only — not financial advice. Always do your own due diligence.
Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through.
A sustained hospital CapExCapital expendituresCash spent on acquiring or upgrading property, plant, and equipment. Splits into maintenance capex (sustaining current capacity) and growth capex (expanding capacity). freeze slows Mako placements, while aggressive GPO negotiations compress implant ASPs, pushing operating margins below 19% and compressing the multiple.
SYK's PEG of 2.51 compresses to the med-tech peer median of 1.56 as Mako-driven growth normalizes.
Hospital GPOs successfully leverage increased competition to drive down orthopaedic implant pricing.
Macroeconomic pressures severely constrain hospital capital expenditure budgets, halting Mako placements.
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
